

## SUPPLIMENTARY FILE 1

### iSCAN: An RT-LAMP-coupled CRISPR-Cas12 module for rapid, sensitive detection of SARS-CoV-2


Zahir Ali<sup>1,\*</sup>, Rashid Aman<sup>1,\*</sup>, Ahmed Mahas<sup>1,\*</sup>, Gundra Sivakrishna Rao<sup>1</sup>, Muhammad Tehseen<sup>3</sup>, Tin Marsic<sup>1</sup>, Rahul Salunke<sup>2</sup>, Amit K. Subudhi, Sharif M. Hala, Samir M. Hamdan<sup>3</sup>, Arnab Pain<sup>2</sup>, Norhan Hassan<sup>1</sup>, and Magdy M. Mahfouz<sup>1,†</sup>

<sup>1</sup>*Laboratory for Genome Engineering and Synthetic Biology, Division of Biological Sciences, 4700 King Abdullah University of Science and Technology, Thuwal 23955-6900, Saudi Arabia.* <sup>2</sup>*Pathogen Genomics Laboratory, BESE Division, King Abdullah University of Science and Technology (KAUST), Thuwal, Saudi Arabia.* <sup>3</sup>*Laboratory of DNA Replication and Recombination, Biological and Environmental Sciences and Engineering Division, King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Saudi Arabia.*

<sup>†</sup>**Correspondence:** Magdy M. Mahfouz (magdy.mahfouz@kaust.edu.sa)


\*These authors contributed equally: Zahir Ali, Rashid Aman, and Ahmed Mahas

**Key words:** COVID-19, SARS-CoV-2, RT-LAMP, CRISPR-Cas12, nucleic acid detection, biosensors, diagnostics




**Supplementary Figure 1: Assessment of enzyme activity and performance of the in-house produced proteins.**

- A) Visualization of the amplicons in agarose gel after RT-LAMP amplification of E-gene; E-T: E-gene detection in Tris buffer, E-H: E-gene detection in HEPES buffer, +ve: E-gene detection with commercial enzymes, N1: sample without crRNA, N2: sample with NS-crRNA, NTC: No template control.
- B) Cas12a based restriction of target dsDNA. Visualization of the fragments generated by Cas12a cis-cleavage of the target regions in agarose gel.
- C) Visual fluorescence readout after Cas12a collateral activity; E-T: E-gene detection in Tris buffer, E-H: E-gene detection in HEPES buffer, +ve: E-gene detection with commercial enzymes, N1: sample without crRNA, N2: sample with NS-crRNA, NTC: sample without template.
- D) Quantification of fluorescence signal after Cas12a collateral cleavage of reporters; E-T: E-gene detection in Tris buffer, E-H: E-gene detection in HEPES buffer, +ve: E-gene detection with commercial enzymes, N1: sample without crRNA, N2: sample with NS-crRNA, NTC: sample without template. Values are shown as mean  $\pm$  SD (n=3).




**Supplementary Figure 2: RT-LAMP and Cas12a time course optimization of detection assay duration.**

The figure depicts different combinations of RT-LAMP assay and Cas12a duration times. Synthetic SARS-CoV-2 RNA was used at 10 Copies per reaction. NTC: no template control. Values are shown as mean  $\pm$ SD (n=4).




**Supplementary Figure 3: Detection of SARS-CoV-2 RNA extracted from patient samples**

- A) RT-LAMP generated amplification products with primer set targeting E-gene in agarose gel. S - RNA isolated from different clinical samples: +ve: synthetic SARS-CoV-2 RNA; NTC: no template control. M: Marker.
- B) Fluorescence signal of different clinical samples after Cas12a-based detection assay using FAM- Q reporter; E-crRNA: assay performed with E-gene crRNA, NS-crRNA: assay performed with non-specific crRNA. Values are shown as mean  $\pm$ SD (n=3).
- C) Fluorescence signal of the samples after Cas12a-based detection assay using commercial HEX reporter; E-crRNA: assay performed with E-gene crRNA, NS-crRNA: assay performed with non-specific crRNA. Values are shown as mean  $\pm$ SD (n=4).




**Supplementary Figure 4: Cas12a detection of SARS-CoV-2 RNA extracted from 24 patient samples using *E* gene assay**

- A) RT-LAMP amplification product of E-gene. Positive control: RT-LAMP with synthetic RNA. NTC: No template control.
- B) Cas12a-based fluorescence detection performed with E-gene crRNA. Values are shown as mean  $\pm$ SD (n=3).




**Supplementary Figure 5: Cas12a detection of SARS-CoV-2 RNA extracted from 24 patient samples using the *N* gene assay**

- A) Visual readout of the results using lateral flow strips
- B) Visualization of RT-LAMP generated amplification products in agarose gel.



**Supplementary Figure 6: AapCas12b and AacCas12b cis- and trans cleavage activity assay**

- A) AapCas12b and AacCas12b cis cleavage activity assay performed at 62°C for 30 minutes
- B) AapCas12b and AacCas12b trans cleavage activity assay. Values shown as mean  $\pm$ SD (n=3).



**Supplementary Figure 7: Optimization of Cas12b detection activity**

- Comparison between the spotted one-pot and all mixed one-pot reactions for detection of SARS-CoV-2 synthetic RNA. NTC: No template control. Values are shown as mean  $\pm$  SD (n=3).
- Determination of Cas12b spotted one-pot LoD using synthetic RNA in a serial dilution series.
- Representatives of lateral flow readouts for detection of SARS-CoV-2 in 4 clinical samples with spotted one-pot Cas12b detection.

**Supplementary Table 1: LAMP Primers**

Primer Name	Sequence	Targeted region
Gene N-B-F3 *	ACCGAAGAGCTACCAGACG	N gene-1
Gene N-B-B3 *	TGCAGCATTGTTAGCAGGAT	N gene-1
Gene N-B-FIP *	TCTGGCCCAGTTCCTAGGTAGTTCGTGGTGGTGACGGTAA	N gene-1
Gene N-B-BIP*	AGACGGCATCATATGGGTTGCACGGGTGCCAATGTGATCT	N gene-1
Gene N-B-LF *	CCATCTTGGACTGAGATCTTCATT	N gene-1
Gene N-B-LB *	ACTGAGGGAGCCTTGAATACA	N gene-1
F3-N3-1	CCGAAGAGCTACCAGACGAA	N gene-2
B3-N3-1	TGTAGCACGATTGCAGCATT	N gene-2
FIP-N3-1	TCTGGCCCAGTTCCTAGGTAGTTGGTGGTGACGGTAAAATGAAAG	N gene-2
BIP-N3-1	AGACGGCATCATATGGGTTGCACGGGTGCCAATGTGATCT	N gene-2
LF-N3-1	AGAAATACCATCTTGGACTGAG	N gene-2
LB-N3-1	ACTGAGGGAGCCTTGAATACAC	N gene-2
F3-E-2	GTACTCATTCTGTTCGGAAG	E gene
B3-E-1	AGGAACCTAGAAGAACATTAGAT	E gene
FIP-E-2	GGATGGCTAGTGTAACTAGCAAGGGTACGTTAATAGTTAATAGCGT	E gene
BIP-E-2	CGCTTCGATTGTGCGTAGAGAGTAAACGTAAAAAGAAGGTT	E gene
LF-E-2	ACCACGAAAGCAAGAAAAAG	E gene
LB-E-1	GCTGCAATATTGTTAACGTGAGTCT	E gene

\* Primers used in [1].

**Supplementary Table 2: Primers used to for *in vitro* transcription and PCR amplification of target genes.**

Primer Name	Sequence	Purpose
N gene-F	GAAATTAATACGACTCACTATAAGGGAG GCTTCTAAGAACGCCTCGGC	To PCR amplify N gene-2 out of IDT kit control.
N gene-R	GGCTCTGTTGGTGGGAATG	To PCR amplify N gene-2 out of IDT kit control.
T7-3G IVT primer	GAAATTAATACGACTCACTATAAGGG	<ul style="list-style-type: none"> <li>- To anneal with Cas12a crRNA oligos for in vitro transcription</li> <li>- To use as F primer to amplify Cas12b sgRNAs</li> </ul>

**Supplementary Table 3: SARS-CoV-2 gBlocks targeted sequences**

E gene	<pre> gaaatataacgactcactataggGGGAACCAATTATGATGAACCGACGACGACTA CTAGCGTGCCTTGTAAGCACAAGCTGATGAGTACGAACCTATGTACTCA TTCGTTCGGAAGAGACAGGTACGTTAATAGTTAATAGCGTACTTCTTT TCTTGCTTCGTTGCTGTTACGTTACAGCCATCCTTACTGCGCT TCGATTGTGTGCGTACTGCTGCAATATTGTTAACGTGAGTCTTGTAAAAC CTTCTTTTACGTTACTCTCGTGTAAAAATCTGAA </pre>
--------	---

**Supplementary Table 4: LbCas12a crRNAs and Cas12b sgRNAs**

Cas Enzyme	gRNA Sequence 5`-3`	Genomic Region
LbCas12a	GTAACTAGCAAGAATACCACTACACTTAGTAGAA ATTACCCTATAGTGAGTCGTATTAATTTC	E gene
	GGACTTCCCTATGGTGCTAAATCTACACTTAGTAGAA ATTACCCTATAGTGAGTCGTATTAATTTC	N gene
Cas12b	ATATTGCAGCAGTACGCACAGTGCCACTTCTCAGATT TGAG	E gene
	GCTGGACTTCCCTATGGTGCCTGCCACTTCTCAGATT GAG	N gene
Cas12b scaffold-F	GAAATTAATACGACTCACTATAAGGGTAGAGGACA GAATTTTCAACGGGTGTGCCAATGCCACTTCCAG GTGGCAAAGCCCCTTGAGCTTCtcaaatctgaGAAGTGGCA C	
Cas12b scaffold-R	GTGCCACTTCtcaagattgaGAAGCTAACGGGCTTGCCA CCTGGAAAGTGGCCATTGGCACACCCGTTGAAAAATT CTGTCCTCTAGACCCTATAGTGAGTCGTATTAATTTC	

## **Reference**

1. Zhang, Y., et al., *Rapid Molecular Detection of SARS-CoV-2 (COVID-19) Virus RNA Using Colorimetric LAMP*. medRxiv, 2020.